The PI3-kinase-Akt Pathway Promotes Mesangial Cell Survival and Inhibits Apoptosis in Vitro Via NF-kappa B and Bad
Overview
Affiliations
While the serine/threonine protein kinase Akt has attracted attention as a mediator of survival (anti-apoptotic) signal, the regulation and function of the PI3-kinase-Akt pathway in mesangial cells is not well known. To explore the significance of the PI3-kinase-Akt pathway, this study used PI3-kinase inhibitors (Wortmannin and LY294002) and recombinant adenoviruses encoding a dominant-active mutant of Akt (AxCAmyrAkt) and a dominant-negative mutant of Akt (AxCAAkt-AA) in cultured rat mesangial cells. Apoptotic signals were measured by nucleosomal laddering of DNA, caspase 3 assay, and cell death detection ELISA. The PI3 kinase inhibitors and dominant-negative mutant of Akt increased the apoptotic signals in the presence of platelet-derived growth factor (PDGF), while the dominant-active mutant of Akt prevented apoptosis induced by a serum-free medium. In separate experiments, we further investigated downstream signals of Akt in mesangial cells. While PDGF activated NF-kappa B and phosphorylated Bad, these reactions were inhibited by overexpression of the dominant-negative mutant of Akt as well as the PI3-kinase inhibitors. These data indicate, firstly, that Akt is phosphorylated by PDGF, and secondly, that the activated Akt prevents apoptotic changes via activation of NF-kappa B and phosphorylation of Bad in mesangial cells. This study investigated whether it is Bad phosphorylation or NF-kappa B activation that provides the anti-apoptotic effects of Akt, and the data suggested that NF-kappa B is probably the principal contributor to the downstream activation of the PI3-kinase-Akt pathway. The findings suggest that the PI3-kinase-Akt pathway acts as a survival signal and plays a key role in the regulation of apoptotic change in mesangial cells principally via NF-kappa B.
Environmental pollutants and phosphoinositide signaling in autoimmunity.
Ren C, Carrillo N, Cryns V, Anderson R, Chen M J Hazard Mater. 2023; 465:133080.
PMID: 38091799 PMC: 10923067. DOI: 10.1016/j.jhazmat.2023.133080.
Breast Cancer Chemoresistance: Insights into the Regulatory Role of lncRNA.
Ahmadpour S, Orre C, Bertevello P, Mirebeau-Prunier D, Dumas J, Desquiret-Dumas V Int J Mol Sci. 2023; 24(21).
PMID: 37958880 PMC: 10650504. DOI: 10.3390/ijms242115897.
Beyaz H, Uludag H, Kavaz D, Rizaner N Adv Exp Med Biol. 2021; 1347:163-181.
PMID: 34287795 DOI: 10.1007/5584_2021_648.
Xia S, Wu J, Zhou W, Zhang M, Zhao K, Liu J Cell Death Dis. 2021; 12(6):570.
PMID: 34108444 PMC: 8190073. DOI: 10.1038/s41419-021-03853-y.
Molecular Investigation on a Triple Negative Breast Cancer Xenograft Model Exposed to Proton Beams.
Cammarata F, Forte G, Broggi G, Bravata V, Minafra L, Pisciotta P Int J Mol Sci. 2020; 21(17).
PMID: 32882850 PMC: 7503243. DOI: 10.3390/ijms21176337.